These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33380426)

  • 1. Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation.
    Lee YH; Im E; Hyun M; Park J; Chung KC
    J Biol Chem; 2021; 296():100245. PubMed ID: 33380426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
    Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.
    Ryoo SR; Jeong HK; Radnaabazar C; Yoo JJ; Cho HJ; Lee HW; Kim IS; Cheon YH; Ahn YS; Chung SH; Song WJ
    J Biol Chem; 2007 Nov; 282(48):34850-7. PubMed ID: 17906291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.
    Liu F; Liang Z; Wegiel J; Hwang YW; Iqbal K; Grundke-Iqbal I; Ramakrishna N; Gong CX
    FASEB J; 2008 Sep; 22(9):3224-33. PubMed ID: 18509201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
    Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
    Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
    Jung MS; Park JH; Ryu YS; Choi SH; Yoon SH; Kwen MY; Oh JY; Song WJ; Chung SH
    J Biol Chem; 2011 Nov; 286(46):40401-12. PubMed ID: 21965663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
    Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
    Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
    Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
    Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
    Yin X; Jin N; Shi J; Zhang Y; Wu Y; Gong CX; Iqbal K; Liu F
    Sci Rep; 2017 Apr; 7(1):619. PubMed ID: 28377597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion.
    Yin X; Jin N; Gu J; Shi J; Zhou J; Gong CX; Iqbal K; Grundke-Iqbal I; Liu F
    J Biol Chem; 2012 Aug; 287(36):30497-506. PubMed ID: 22767602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
    Gehlot P; Pathak R; Kumar S; Choudhary NK; Vyas VK
    Bioorg Med Chem; 2024 Nov; 113():117925. PubMed ID: 39357433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.
    Granno S; Nixon-Abell J; Berwick DC; Tosh J; Heaton G; Almudimeegh S; Nagda Z; Rain JC; Zanda M; Plagnol V; Tybulewicz VLJ; Cleverley K; Wiseman FK; Fisher EMC; Harvey K
    Sci Rep; 2019 May; 9(1):7322. PubMed ID: 31086297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7.
    Chu D; Lei L; Gu S; Liu F; Wu F
    Biochem Pharmacol; 2024 Jun; 224():116233. PubMed ID: 38663682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome.
    Shi J; Zhang T; Zhou C; Chohan MO; Gu X; Wegiel J; Zhou J; Hwang YW; Iqbal K; Grundke-Iqbal I; Gong CX; Liu F
    J Biol Chem; 2008 Oct; 283(42):28660-9. PubMed ID: 18658135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.